[ RadSafe ] ICCA-LRI Workshop Presentation

[Scott, Bobby]

Hi all,

 

I gave a presentation at the International Council of Chemical
Associations (ICCA) Long-Range Research Initiative (LRI) Workshop held
in Santa Fe, New Mexico, USA June 11-12, 2013.  The workshop was titled
"What is Normal? Implications for Chemical Safety Assessment." My
presentation was titled "Radiation adaptive responses and implications
for better than normal health." I discussed data for each of the
following demonstrated adaptive-response benefits (activated natural
protection, abbreviated ANP) of "low radiation doses":

 

1. X-ray ANP against carbon-tetrachloride-induced liver damage in mice.

2. Inhaled radon ANP against carbon-tetrachloride-induced liver and
kidney damage in mice.

3. Gamma-ray ANP against autoimmune disease in mice that normally
develop the disease with high frequency.

4. Gamma-ray ANP against diabetes in mice that normally develop the
disease with high frequency.

5. Gamma-ray ANP against collagen-induced arthritis in mice.

6. Gamma-ray ANP against benzo(a)pyrene (cigarette-smoke-carcinogen)
induced multiple lung tumors in mice.

7. Gamma-ray ANP against methylcholanthrene-induced skin tumors in mice.

8. Gamma-ray ANP against high-dose Pu-239 alpha-radiation-induced lung
tumors in rats.

9. Inhaled radon (residential) ANP against lung tumors in humans caused
by cigarette smoke carcinogens and other agents. Maximum ANP occurs at
average radon concentrations around 4 pCi/L (about 150 Bq/cubic meter).

 

Most of the above low-dose radiation research was conducted by others in
Japan and in the United States. If anyone would like a pdf file of the
slides presented, let me know via e-mail sent to bscott at LRRI.org (but
not to the RadSafe Digest list). 

 

Best wishes,

Bobby

B. R. Scott

Lovelace Respiratory Research Institute

Albuquerque, NM, USA

 




*******************************************************************************

This e-mail and any files are protected by the Electronic Communications Privacy
Act, 18 U.S.C. Sections 2510-2521. Its intended to be delivered only to the named
addressee(s) and its content is confidential and privileged. If you are not the
intended recipient or the person responsible for delivering the e-mail to the
intended recipient, be advised that you have received this e-mail in error and
that any use, dissemination, forwarding, printing, or copying of this e-mail is
prohibited. If you have received this e-mail in error, please notify the sender
by replying to this message and delete this e-mail immediately. Nothing in this
communication, either written or implied, constitutes or should be construed as a
legally binding agreement between the parties with respect to the subject matter
herein.